The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | - | 838 | 3,794 | - |
| Total operating expenses | - | 49,446 | 163,536 | - |
| Total other income, net | - | 2,529 | 4,679 | - |
| Net loss | -49,122 | -46,079 | -50,582 | -104,481 |
| Stock-based compensation expense | 4,644 | 4,515 | 12,747 | 12,006 |
| Non cash lease expense | 2,843 | 2,603 | 2,334 | 4,761 |
| Depreciation expense | 1,856 | 1,876 | 1,881 | 3,564 |
| Deferred income taxes | - | - | - | 0 |
| Accrued settlement payment related party | - | 0 | 0 | 0 |
| Amortization of premiums and discount on short-term investments | 431 | 788 | 574 | 575 |
| Change in fair value of short-term investment related party | 0 | 539 | 1,454 | -1,561 |
| Collaboration receivable related party | 0 | - | -120 | 120 |
| Prepaid expenses and other current assets | -1,221 | -2,596 | -1,297 | -652 |
| Accounts payable | 3,552 | -581 | 3,038 | -1,461 |
| Accrued expenses and other current liabilities | -4,502 | 1,600 | -1,070 | -1,690 |
| Deferred revenue related party | -856 | -751 | -1,175 | -2,433 |
| Lease liabilities | -1,915 | -1,708 | -1,601 | -2,053 |
| Net cash used in operating activities | -42,710 | -37,256 | -35,039 | -90,269 |
| Maturities of investments | 50,888 | 39,100 | 42,431 | 14,250 |
| Sales of investments related party | - | 5,400 | - | - |
| Purchases of investments | 7,283 | 15,880 | 134,306 | 55,227 |
| Purchases of property and equipment | 214 | 290 | 247 | 3,994 |
| Return (payments) of security deposits | - | - | 0 | - |
| Return (payment) of security deposit | - | 0 | - | - |
| Net cash provided by (used in) investing activities | 43,391 | 28,330 | -92,122 | -44,971 |
| Proceeds from follow-on offering, net of issuance costs | - | 10 | 138,380 | 0 |
| Net proceeds from stock option exercises | 393 | 408 | 373 | 0 |
| Proceeds from espp offerings | - | 144 | 0 | 197 |
| Proceeds from issuance of common stock under the bms securities purchase agreement related party | - | 0 | 0 | - |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | - | 0 | 0 | 0 |
| Proceeds from research and development funding liability | 0 | 0 | 6,000 | 6,000 |
| Net cash provided by financing activities | 393 | 562 | 144,753 | 6,197 |
| Net change in cash, cash equivalents, and restricted cash | 1,074 | -8,364 | 17,592 | -129,043 |
| Cash, cash equivalents, and restricted cash at beginning of period | 76,723 | 85,087 | 196,538 | - |
| Cash, cash equivalents, and restricted cash at end of period | 77,797 | 76,723 | 85,087 | - |
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)